Levosimendan reduces segmental pulmonary vascular resistance in isolated perfused rat lungs and relaxes human pulmonary vessels

Annette Dorothea Rieg¹ *, Said Suleiman², Nina Andrea Bünting², Eva Verjans³, Jan Spillner¹, Heike Schnöring⁴, Sebastian Kalverkamp⁴, Thomas Schröder⁵, Saskia von Stillfried⁶, Till Braunschweig⁶, Gereon Schälte¹, Stefan Uhlig², Christian Martin²

¹ Department of Anaesthesiology, Medical Faculty Aachen, Rhenish Westphalian Technical University, Aachen, Germany, ² Institute of Pharmacology and Toxicology, Medical Faculty Aachen, Rhenish Westphalian Technical University, Aachen, Germany, ³ Department of Paediatrics, Medical Faculty Aachen, Rhenish Westphalian Technical University, Aachen, Germany, ⁴ Department of Cardiac and Thoracic Surgery, Medical Faculty Aachen, Rhenish-Westphalian Technical University, Aachen, Germany, ⁵ Department of Surgery, Luisenhospital Aachen, Aachen, Germany, ⁶ Institute of Pathology, Medical Faculty Aachen, Rhenish-Westphalian Technical University, Aachen, Germany

* arieg@ukaachen.de

Abstract

Introduction

Levosimendan is approved for acute heart failure. Within this context, pulmonary hypertension represents a frequent co-morbidity. Hence, the effects of levosimendan on segmental pulmonary vascular resistance (PVR) are relevant. So far, this issue has been not studied. Beyond that the relaxant effects of levosimendan in human pulmonary vessel are unknown. We addressed these topics in rats’ isolated perfused lungs (IPL) and human precision-cut lung slices (PCLS).

Material and methods

In IPL, levosimendan (10 μM) was perfused in untreated and endothelin-1 pre-contracted lungs. The pulmonary arterial pressure (P_PA) was continuously recorded and the capillary pressure (P_cap) was determined by the double-occlusion method. Thereafter, segmental PVR, expressed as precapillary (R_pre) and postcapillary resistance (R_post) and PVR were calculated. Human PCLS were prepared from patients undergoing lobectomy. Levosimendan-induced relaxation was studied in naïve and endothelin-1 pre-contracted PAs and PVs. In endothelin-1 pre-contracted PAs, the role of K⁺-channels was studied by inhibition of K_ATP-channels (glibenclamide), BK_Ca²⁺-channels (iberiotoxin) and K_v-channels (4-aminopyridine). All changes of the vascular tone were measured by videomicroscopy. In addition, the increase of cAMP/GMP due to levosimendan was measured by ELISA.

Results

Leverosimendan did not relax untreated lungs or naïve PAs and PVs. In IPL, levosimendan attenuated the endothelin-1 induced increase of P_PA, PVR, R_pre and R_post. In human PCLS,
levosimendan relaxed pre-contracted PAs or PVs to 137% or 127%, respectively. In pre-contracted PAs, the relaxant effect of levosimendan was reduced, if K<sub>ATP</sub>- and K<sub>v</sub>-channels were inhibited. Further, levosimendan increased cGMP in PAs/PVs, but cAMP only in PVs.

**Discussion**

Levosimendan reduces rats’ segmental PVR and relaxes human PAs or PVs, if the pulmonary vascular tone is enhanced by endothelin-1. Regarding levosimendan-induced relaxation, the activation of K<sub>ATP</sub>- and K<sub>v</sub>-channels is of impact, as well as the formation of cAMP and cGMP. In conclusion, our results suggest that levosimendan improves pulmonary hemodynamics, if PVR is increased as it is the case in pulmonary hypertension.

**Introduction**

The Ca<sup>2+</sup>-sensitizer levosimendan exerts beneficial cardiovascular properties [1], decreases patients’ mortality in acute heart failure [2] and improves the outcome of cardiac surgical patients with left ventricular dysfunction [3,4]. Recently, levosimendan even convinced in outpatients, as the intermittent intravenous application of levosimendan reduced their hospitalization due to heart failure [5].

Beyond the inotropic effects of levosimendan, its dilating properties on the pulmonary circulation are of considerable impact [6–8]. They contribute to the success of levosimendan within the therapy of right heart failure and pulmonary arterial hypertension (PAH) [9–13]. However, studies targeting the relaxant effect of levosimendan in the pulmonary vascular bed are scare and most of them addressed pulmonary arteries (PAs) [6,8,11,14]. Although, relaxation of pulmonary veins (PVs) would be beneficial within pulmonary hypertension (PH) due to left-heart disease (LHD), which is the most common cause of PH [15] and primarily affects the pulmonary venous bed [16–18]. Recently, our group addressed this topic and studied the relaxant effects of levosimendan in central PAs and PVs using precision-cut lung slices (PCLS) of guinea pigs [8]. We found that levosimendan relaxes PAs and PVs via common (K<sub>ATP</sub>-channels, cAMP/cGMP) and different (BK<sub>Ca</sub><sup>2+</sup>-and K<sub>v</sub>-channels only in PAs) mechanisms. Although, this study proved the relaxant effect of levosimendan in PAs and PVs and further illustrates that both vessel types respond different to the same stimulus [19,20], it has several restrictions. First of all, we studied PAs and PVs deriving from a central part of the lung which primarily do not determine pulmonary vascular resistance (PVR) [21,22]. Thus, with regard to PVR and particularly with regard to segmental PVR (precapillary (R<sub>pre</sub>) and postcapillary resistance (R<sub>post</sub>)), the effects of levosimendan remain unknown. Second, disregarding from PAs or PVs, the various segments along the pulmonary bed react quite different to various pharmacological stimuli [20]. So far, it is unexplored, whether levosimendan also exerts relaxation in a more peripheral part of the lung. Third, remarkable differences exist between various species [23–25]; hence we do not know if levosimendan-induced relaxation is also relevant for human PAs and PVs.

To address these items, we applied levosimendan in isolated perfused lungs (IPL) of rats using endothelin-1 (ET-1) to increase PVR. Further, we evaluated the relaxant effect of levosimendan in human PAs or PVs which derive from a peripheral part of the lung, as well as its effect on the formation of cAMP and cGMP. In addition, we studied the role of K<sub>ATP</sub>-, K<sub>v</sub>- and BK<sub>Ca</sub><sup>2+</sup>-channels within levosimendan-induced relaxation in human PAs (PCLS).
Material and methods

Animals and human lung tissue

Female Wistar rats (250 ± 50 g) were purchased from Charles River (Sulzfeld, Germany). All animal studies were approved by the Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen (ID: 8.87–51.05.20.10.245) and all experiments were strictly performed due to the Directive 2010/63/EU of the European Parliament.

Human PCLS were prepared from patients undergoing lobectomy due to lung cancer. After pathological inspection, cancer free tissue from a peripheral part of the lung was used. Patients with PH (histology) were excluded. The study was approved by the local ethics committee (EK 61/09) of the Medical Faculty Aachen, Rhenish-Westphalian Technical University (RWTH) Aachen and all experiments were performed according to the Declaration of Helsinki. All patients gave written informed consent.

Isolated perfused rat lungs

Rat lungs were prepared as described [26,27]. Briefly, intraperitoneal anaesthesia was performed (pentobarbital: 95 mg kg⁻¹) and verified by missing reflexes. The rat was bled, the trachea cannulated and the lung ventilated with positive pressure (70 breaths/min). The apex of the left ventricle was cut and cannulas were placed in the pulmonary artery (perfusion inflow) and in the left atrium (perfusion outflow). The lung was perfused at constant flow (12.5 mL/min) with Krebs-Henseleit buffer, containing 2% bovine serum albumin, 0.1% glucose, 0.3% HEPES and 50 nM salbutamol to prevent bronchoconstriction [28]. The temperature of the perfusate was maintained at 37˚C with a water bath and the pH was adjusted between 7.35 and 7.45 by carbon dioxide gassing. Heart and lungs were removed and set into a negative-pressure chamber. To prevent the formation of lung oedema during constant flow perfusion and negative pressure ventilation, a pressure balancing chamber was established in the perfusion outflow which was connected to the artificial thorax chamber. To prevent atelectasis of the lung, every 5 minutes a deep breath was applied. The tidal volume (TV), compliance (Cdyn), resistance (Res), pulmonary arterial pressure (P_{PA}), pulmonary atrial pressure (P_{LA}) and the flow were continuously monitored. As soon as respiratory and haemodynamic variables remained stable over 10 minutes, ET-1 (final concentration in the buffer: 15 nM) was added to the recirculating perfusion buffer (total volume 200 mL) to enhance PVR which was calculated as followed: PVR = (P_{PA}−P_{LA}) x 80 / flow. Ten minutes after the application of ET-1, levosimendan (10 μM) was perfused. Thereafter, changes of P_{cap} were measured every 10 minutes by the double-occlusion method (DOC) [27]. Therefore, two magnet valves mounted before and after the lung were simultaneously clamped to interrupt the perfusion in-/outflow at the same time. R_{post} and R_{pre} were calculated as followed: R_{post} = \frac{P_{cap}−P_{LA}}{flow} and R_{pre} = \frac{P_{PA}−P_{cap}}{flow}.

PCLS

Human lung lobes were filled via a main bronchus with 1.5% low-melting agarose and cooled on ice. Tissue cores were prepared and cut into approximately 300 μm thick slices with a tissue slicer (Alabama Research & Development, Munford, AL, USA). PCLS were incubated at 37˚C and the medium was changed several times in order to wash out the agarose. PCLS are known to be at least 72 h viable [29,30].

Measurements of cAMP and cGMP

To analyse cAMP and cGMP, human PAs and PVs from tissue cores were cannulated by a plastic catheter (14 gauges), isolated, flushed with levosimendan (100 μM and 1 μM) or
medium (controls) and incubated for 30 minutes in medium. Afterwards, they were frozen by liquid N\textsubscript{2}. Cyclic AMP and cGMP were quantified with ELISA-kits following the manufacturer’s protocol. For stabilisation, all samples and standards were acetylated. To measure cAMP, all samples were diluted 1:2 with 0.1 M HCL. Both ELISAs were evaluated at 405 nM (GENIOS, Tecan, Switzerland).

**Identification of the vessels, histology**

Human pulmonary vessels were identified by their anatomical landmarks. PAs accompany the airways and PVs lie aside. After the experiments, the identification of the vessels was histologically confirmed by elastica van Gieson-staining, where PAs show an internal and external elastic lamina, in contrast to PVs which show only an external elastic lamina [31].

**Measurements and imaging**

The kinetics of levosimendan was studied. Human PCLS were exposed 5 minutes to each concentration of levosimendan. If pre-constriction was required, they were pre-treated 1h with ET-1. If K\textsuperscript+-channels were inhibited, PCLS were pre-treated 1 h with 10 μM glibenclamide (K\textsubscript{ATP}-channels), 100 nM iberiotoxin (BK\textsubscript{Ca}\textsuperscript{2+}-channels) or 5 mM 4-aminopyridine (K\textsubscript{v}-channels). If both were required, PCLS were exposed at once to both. Before the measurements, the initial vessel area (IVA) was defined as 100% and any relaxant or contractile effect (ET-1) was indicated as "Change of IVA [%]". To compare relaxation of pre-treated vessels, the vessel area was defined after the pre-treatment duration of 1 h again as 100%. Hence, a vessel area <100% indicates contraction and a vessel area >100% indicates relaxation. Concentration-response curves of levosimendan were performed and the effects were indicated again as "Change of IVA [%]". Control experiments were performed on consecutive sections. Pulmonary vessels were imaged by a digital video camera (Leica Viscam 1280 or Leica DFC 280). The images were analysed with Optimas 6.5 (Media Cybernetics, Bothell, WA) [29].

**Agents and culture medium**

All agents were bought from Tocris Bioscience (Ellisville, Missouri, USA), except levosimendan which was from Sigma-Aldrich (Steinheim, Germany) and ET-1 which was from BIOTRENDS (Wangen, Switzerland).

**Statistics**

Statistics was conducted using SAS software 9.3 (SAS Institute, Cary, North Carolina, USA) and GraphPad Prism 5.01 (GraphPad, La Jolla, USA). The data in Fig 1 were analysed using a linear mixed model analysis (LMM) with variance components (VC) for the covariance matrix; EC\textsubscript{50} values were calculated by the standard 4-parameter logistic non-linear regression model (Figs 2 and 3A–3C). The AIC-criterion was used to select the most parsimonious model, i.e. a common bottom, top, slope and EC\textsubscript{50} value in the regression model or the covariance matrix with the least number of parameters. The data in Fig 3D were evaluated by a one-way ANOVA and the data in Fig 4 were analysed by the Mann-Whitney U test. P-values were adjusted for multiple comparisons by the false discovery rate and presented as mean ± SEM. P < 0.05 was considered as significant; (n) indicates the numbers of animals or lung lobes.

**Results**

We studied the Ca\textsuperscript{2+}-sensitizer levosimendan in the IPL using untreated and ET-1 pre-treated rat lungs. In this view, we focused on the pulmonary vascular properties of levosimendan. In
Fig 1. Effect of ET-1 and levosimendan on pulmonary haemodynamics in the IPL. A) Pulmonary arterial pressure (P_{PA}). B) Left atrial pressure (P_{LA}). C) Pulmonary vascular resistance (PVR). D) Pulmonary capillary pressure (P_{cap}). E) Precapillary resistance (R_{pre}). F) Postcapillary resistance (R_{post}). For all: ─ control (n = 8); ─ levosimendan (n = 8); ● 15 nM ET-1 (n = 7); ● 15 nM ET-1 / 10 μM levosimendan (n = 8). A-F: Statistics was performed by a linear mixed model analysis (LMM). P < 0.05 are considered as significant: * p < 0.05, ** p < 0.01 and *** p < 0.001.

https://doi.org/10.1371/journal.pone.0233176.g001

Fig 2. Effect of ET-1 and levosimendan in human PCLS. A) Concentration-response curve of levosimendan in PAs and PVs: ○ naive PAs (n = 5); □ naive PVs (n = 6). B) Concentration-response curve of ET-1: ● naive PAs (n = 7); ● naive PVs (n = 6). C) Concentration-response curve of levosimendan in ET-1 pre-constricted PAs: ○ 100 nM ET-1 (n = 6); ● 100 nM ET-1 / levosimendan (n = 6). D) Concentration-response curve of levosimendan in ET-1 pre-constricted PVs: ○ 50 nM ET-1 (n = 7); ● 50 nM ET-1 / levosimendan (n = 8). B: Statistics was performed by the comparison of EC_{50} values. P < 0.05 are considered as significant.

https://doi.org/10.1371/journal.pone.0233176.g002
In human PCLS, we evaluated the impact of levosimendan-induced relaxation in PAs and PVs. In addition, we studied the impact of $K^+$-channels within the relaxant effect of levosimendan in human PAs.

Fig 3. Role of $K^+$-channels within the relaxant effect of levosimendan in human PCLS. A) Inhibition of $K_{ATP}$-channels (glibenclamide) in ET-1 pre-constricted PAs: $\bullet$ 100 nM ET-1 / 10 $\mu$M glibenclamide (n = 6); $\bullet$ 100 nM ET-1 / 10 $\mu$M glibenclamide / levosimendan (n = 6); $\bullet$ 100 nM ET-1 / levosimendan (n = 6). B) Inhibition of $K_v$-channels (5-amino pyridine) in ET-1 pre-constricted PAs: $\bullet$ 100 nM ET-1 / 5 mM 5-amino pyridine (n = 6); $\bullet$ 100 nM ET-1 / 5 mM 5-amino pyridine / levosimendan (n = 6); $\bullet$ 100 nM ET-1 / levosimendan (n = 6). C) Inhibition of $BK_{Ca}^{2+}$-channels (iberiotoxin) in ET-1 pre-constricted PAs: $\bullet$ 100 nM ET-1 / 100 nM iberiotoxin (n = 5); $\bullet$ 100 nM ET-1 / 100 nM iberiotoxin / levosimendan (n = 5); $\bullet$ 100 nM ET-1 / levosimendan (n = 5). D) Effect of inhibition of $K^+$-channels on the contractile effect of ET-1. A-C: Statistics was performed by the comparison of EC$_{50}$ values. D: Statistic was performed by an one-way ANOVA. $P<0.05$ are considered as significant: $^*$ $P<0.05$, $^*$ $P<0.01$ and $^*$ $P<0.001$. 

https://doi.org/10.1371/journal.pone.0233176.g003

In human PCLS, we evaluated the impact of levosimendan-induced relaxation in PAs and PVs. In addition, we studied the impact of $K^+$-channels within the relaxant effect of levosimendan in human PAs.
Rat IPL: Effect of levosimendan on pulmonary haemodynamics

In the IPL, perfusion with 10 μM levosimendan was started, if baseline values of all parameters were stable for 20 minutes. Pulmonary haemodynamic parameters such as $P_{PA}$, $P_{LA}$, $P_{VR}$, capillary pressure ($P_{cap}$), $R_{pre}$ and $R_{post}$ remained stable during perfusion with levosimendan and did neither differ from baseline values nor from those of untreated control IPLs (Fig 1A–1F; $p > 0.05$).

Next, we studied the effects of levosimendan in ET-1 pre-treated IPLs to increase $P_{PA}$, as a pathophysiological feature of PH. Perfusion of ET-1 (final concentration in the buffer 15 nM) was started, if baseline parameters were stable for 10 minutes. ET-1 significantly increased $P_{PA}$, $P_{VR}$, $P_{cap}$, $R_{pre}$ and $R_{post}$ (Fig 1A and 1C and 1F; $p < 0.001$), whereas $P_{LA}$ remained unchanged (Fig 1B). Perfusion of levosimendan decreased the ET-1 induced increase of $P_{PA}$, $P_{VR}$, $R_{pre}$ (Fig 1A and 1C and 1E; all: $p < 0.01$) and $R_{post}$ (Fig 1F; for 140–180 minutes: $p < 0.05$). Even though, values of all parameters stayed higher than those of untreated control lungs, e.g. $P_{PA}$, $P_{VR}$, $R_{pre}$ (Fig 1A and 1C and 1E; all: $p < 0.01$) and $R_{post}$ (Fig 1F; $p < 0.001$). In addition, levosimendan did not alter the effect of ET-1 on $P_{cap}$ (Fig 1D).

Human PCLS: The relaxant effect of levosimendan in human pulmonary arteries and veins

In human PCLS, we studied the pulmonary vasorelaxant properties of increasing concentrations of levosimendan. Levosimendan did not relax naïve PAs or PVs (Fig 2A). Thus, we decided to pre-contract PAs and PVs with ET-1. To reach a comparable degree of pre-contraction, we treated both with increasing concentrations of ET-1 (Fig 2B). ET-1 contracted PAs and PVs with EC$_{50}$ values of 58 nM and 21 nM, respectively (Fig 2B). Thus, we decided to pre-contract PAs and PVs with 100 nM and 50 nM ET-1, respectively. After pre-contraction, 100 μM levosimendan relaxed PAs up to 137% of IVA with an EC$_{50}$ value of 1.6 μM (Fig 2C).
Levosimendan at 1 μM was also effective, as it relaxed PAs up to 117% of IVA (Fig 2C). Further, 100 μM levosimendan relaxed PVs up to 127% of IVA with an EC$_{50}$ value of 24 μM, whereas 1 μM levosimendan relaxed PVs only to 107% of IVA (Fig 2D). Finally, levosimendan relaxed humans PAs more potently than human PVs (p<0.05).

**Mechanisms contributing to the relaxant effect of levosimendan—K$^+$-channels**

Next, we studied the involvement of K$^+$-channels within the relaxant effect of levosimendan. We studied this issue in human PAs, as they relaxed stronger to levosimendan than human PVs. Inhibition of K$_{ATP}$-channels by glibenclamide decreased the relaxant effect of levosimendan in human PAs and shifted the EC$_{50}$ value from 1.6 to 22 μM (Fig 3A; p<0.01). Inhibition of K$_V$-channels by 4-aminopyridine also decreased levosimendan-induced relaxation, EC$_{50}$ values were displaced rightwards from 1.6 μM to 56 μM (Fig 3B; p<0.01). In contrast, inhibition of BK$_{Ca}^{2+}$-channels did not alter the relaxant effect of levosimendan (Fig 3C). In addition, inhibition of K$^+$-channels did not alter ET-1-induced contraction (Fig 3D).

**Mechanisms contributing to the relaxant effect of levosimendan—cAMP/cGMP**

In human PAs, levosimendan did not enhance intracellular cAMP-levels, neither at 1 or 100 μM (Fig 4A). In contrast, 100 μM levosimendan increased intracellular cAMP in human PVs (Fig 4A; p<0.05), whereas a lower concentration of 1 μM levosimendan was without effect (Fig 4A). Further, levosimendan at 100 μM enhanced intracellular cGMP in PAs and PVs (Fig 4B; p<0.05 for PAs and p<0.01 for PVs), whereas levosimendan at 1 μM had no effect on cGMP levels.

**Discussion**

In ET-1 pre-treated IPLs of the rat, we could prove the lowering effect of levosimendan on total PVR and on segmental PVR, expressed as R$_{pre}$ and R$_{post}$. Beyond that we could show that this effect is relevant for humans, as levosimendan relaxes ET-1 pre-constricted human PAs and PVs from the peripheral part of the lung. Regarding the pulmonary vasorelaxant effects of levosimendan the activation of K$_{ATP}$- and K$_V$-channels, as well as the generation of cAMP/cGMP are of impact.

**ET-1-induced pre-constriction**

We selected ET-1 to enhance the vascular tone in rats lungs and in human PAs/PVs, as ET-1 plays a major role in PH, e.g. ET-1 receptors are up-regulated [32] and ET-1 levels are increased [33,34]. Aside its role as a potent vasoconstrictor, ET-1 mediates proliferation and migration of vascular cells and thus promotes vascular remodelling in PH [35].

**IPL: Pulmonary vascular effects of levosimendan**

In the IPL of the rat, we show that levosimendan reduces the increasing effects of ET-1 on P$_{PA}$, PVR, R$_{pre}$ and R$_{post}$. In contrast, levosimendan was without effect on pulmonary haemodynamics, if P$_{PA}$, PVR, R$_{pre}$ and R$_{post}$ were not enhanced. Our results concerning the effects of levosimendan on P$_{PA}$, resembling the central pulmonary arterial bed are in line with other experimental set-ups [6,36]. In isolated perfused feline lung lobes [6], levosimendan reduced the increasing effects of thromboxane on P$_{PA}$ and in a porcine model of hypoxia-induced PH [36]; levosimendan lowered the hypoxic increase of mean P$_{PA}$ [36]. They are further consistent with a previous work, where levosimendan relaxed central ET-1 pre-constricted PAs from
guinea pigs [8]. Beyond that, the beneficial effects of levosimendan on $P_{PA}$ have been proven in clinical studies with patients suffering to PAH [11,37,38]. In summary, these data confirm the relevance of levosimendan-induced relaxation in central PAs.

In spite of the promising data with levosimendan and its relaxant effect on the central pulmonary arterial bed, relaxation of PAs/PVs from the peripheral pulmonary vascular bed would be much more valuable, as due to its high cross-sectional area, it mainly determines PVR [21,22]. In the present study, levosimendan significantly decreased PVR in ET-1 pre-treated lungs. Further, in hypoxia-induced PH levosimendan lowered the hypoxic increase of PVR [36]. Hence, both results highly suggest that a relevant relaxant effect of levosimendan in peripheral PAs or PVs should also account for levosimendan-induced reduction of PVR. To highlight this issue, we applied the DOC and found that levosimendan decreases segmental arterial and venous PVR, expressed as $R_{pre}$ and $R_{post}$. Both results are of high clinical value, e.g. levosimendan-induced reduction of $R_{pre}$ means that right ventricular afterload decreases which is advantageous in PAH [9–13]. In contrast, levosimendan-induced reduction of $R_{post}$ is of clinical importance in PH due to LHD, as small PVs contributing to PVR relax to levosimendan. In principle, PH due to LHD, also called postcapillary PH resembles the most common cause of PH [15] which mainly affects the pulmonary venous system [16,18]. So far, the effects of levosimendan on $R_{post}$ have been unexplored, as the access to the pulmonary venous bed is quite difficult. In vivo, pulmonary venous pressures must be calculated indirectly from the pulmonary capillary wedge pressure (PCWP) which reflects the pressure in the left atrium [39] or in large PVs [40], but not in small PVs which are aside small PAs mainly responsible for PVR [21,22]. In the IPL, we calculated $R_{post}$ and $R_{pre}$ after determination of $P_{cap}$ by the DOC [27].

**PCLS: Pulmonary vasorelaxant effects of levosimendan**

In PCLS, levosimendan relaxed small human PAs and PVs potently. Thus, our results from the IPL concerning the effect of levosimendan on $R_{pre}$ and $R_{post}$ are supported and the clinical relevance of levosimendan is confirmed.

Levosimendan relaxed human PAs stronger than PVs; hence the present results differ in part from those of a former work analysing the relaxant effect of levosimendan in PAs and PVs from guinea pigs [8]. There, levosimendan relaxed pre-constricted PAs or PVs from guinea pigs comparable, in addition it also relaxed untreated naïve PVs [8]. Reflecting possible reasons for the varying response of human PAs and PVs to levosimendan, the degree of pre-constriction should be considered. Though, human PAs and PVs were comparable pre-constricted with 100 nM and 50 nM ET-1, respectively, as shown in Fig 2B and in a former study [31]. Finally, the degree of pre-constriction should not account for the different relaxant response of human PAs and PVs. In principle, PAs and PVs differ within their anatomical structure [41]. So, it is not entirely surprising that they differ also in their reaction to various stimuli, as it was already shown for cardiovascular agents, NO or prostacyclin [19,42–44]. Indeed, levosimendan does not only exert different vascular responses in respect to the pulmonary arterial or venous belonging of the studied vessel, but also in the dependence to the species, e.g. ET-1 pre-contracted PAs and PVs from the peripheral part of the human lung did not relax comparable to levosimendan, in contrast ET-1 pre-contracted PAs and PVs from the central part of the guinea pig lung relaxed comparable to levosimendan [8]. Certainly, not only different species, but also different vessel sizes were studied. This is of impact, as in dependence of the vessel size and the pulmonary vascular segment; pulmonary vessels exert a certain $K^+$-channel diversity [20] and are differently equipped with $\alpha_1/\beta_1$, receptors [44]. The meaning of the studied species is supported by several studies, e.g. pulmonary vessels from humans...
and guinea pigs varied in their reaction to imatinib [23,24], PDGF-BB [24,45] or milrinone [31]. Finally, to obtain valuable information concerning the vasorelaxant effects of several vasodilators in the human pulmonary vascular bed, human PAs and PVs should be studied.

**PCLS: The role of K⁺-channels within the relaxant effect of levosimendan**

In human PAs, we studied the role of K⁺-channels within the relaxant effect of levosimendan. We found that activation of K_ATP and K_v-channels belongs to the mechanisms beyond, whereas activation of BK_Ca²⁺ is without impact. Our results concerning the role of K_ATP-channels within levosimendan-induced relaxation are in line with previous studies studying PAs and PVs from guinea pigs [8], human internal thoracic arteries [46], human portal veins [47] or feline lung lobes [6]. Accordingly, the impact of K_v-channel-activation within the relaxant effect has been already shown in central PAs from guinea pigs [8] and in porcine coronary arteries [48]. In contrast, our results concerning BK_Ca²⁺-channels are not in line with a former work in central PAs from guinea pigs [8]. There, K_ATP, BK_Ca²⁺- and K_v-channels have been shown to be involved within levosimendan-induced relaxation [8]. In the present work, we studied human PAs deriving from a peripheral part of the lung; thus resistance PAs which are only rarely equipped with BK_Ca²⁺-channels [20]. In contrast, previously we studied central PAs from guinea pigs [8], thus conduit PAs which are densely equipped with BK_Ca²⁺-channels [20]. Finally, the diverging results are explainable by the heterogeneity of K⁺-channels along the pulmonary vasculature [20]. Apart from that, levosimendan-induced activation of BK_Ca²⁺-channels has been already shown in porcine coronary arteries [48] and human internal thoracic arteries [46]. Above all, levosimendan-induced activation of K⁺-channels does not only account for its vasorelaxant effects, but also alters vascular remodeling in PH [14]. Revermann et al. [14] showed that levosimendan-induced activation of K_ATP-channels attenuates the pulmonary vascular remodeling due to monocrotaline in rats. This issue is of particular interest in PH, as decreased expression and/or activity of K⁺-channels resembles an important pathophysiological aspect of pulmonary vascular remodeling in PH [35]. Hence, levosimendan could fulfill two therapeutic requirements within the therapy of PH, 1) pulmonary vascular relaxation and 2) reversal of pulmonary vascular remodelling.

**Human PAs and PVs–the role of levosimendan-induced generation of cAMP and cGMP**

Levosimendan did not relax naïve human PAs/PVs, although 100 μM levosimendan increased cGMP in human PAs/PVs and cAMP in human PVs. In contrast, a lower concentration of 1 μM levosimendan did not influence the generation of cAMP or cGMP. Due to the fact that naïve human PAs/PVs did not relax to 100 μM levosimendan, although 100 μM levosimendan increased cAMP/cGMP-levels, it is most likely that levosimendan-induced generation of cAMP/cGMP is not relevant for its relaxant effect in the human pulmonary circulation. This conclusion is reinforced by the fact that plasma levels of 100 μM levosimendan are not reached in humans [49].

A previous study in central PAs and PVs from guinea pigs [8] indicates a cGMP-raising potential of levosimendan [8], there inhibition of cGMP did not alter the relaxant effect of levosimendan. In contrast, studies in coronary vessels showed increased cGMP-levels due to levosimendan which were relevant for its relaxant potential [14]. Regarding the effect of levosimendan on cAMP, our results are in contrast to a previous study [8]. There, levosimendan raised cAMP in naïve central PAs/PVs from guinea pigs [8]. In PVs from guinea pigs, the cAMP-increase was crucial for levosimendan-induced relaxation [8]. Beyond that, the raising effect of levosimendan on cAMP was shown in porcine coronary arteries [50]. In principle, the
effects of levosimendan on cAMP are explainable by its inhibiting effects on PDE-III [51] and its stimulating effects on adenyl cyclase [8]. Both have been shown to be expressed in the human vascular bed [52]. Anyway, our results concerning the effects of levosimendan on cAMP differ in PAs from humans and guinea pigs [8]. Possibly, the expression of PDE-III and adenyl cyclase differs in dependence to the studied species and the vascular segment.

Conclusion

Levosimendan lowers $R_{\text{pre}}$, $R_{\text{post}}$, $P_{\text{PA}}$ and PVR if the pulmonary vascular tone is enhanced by ET-1 resembling a major pathological aspect of PH. The impact of these results is enforced by the fact that levosimendan relaxes human pulmonary vessels at concentrations which are clinically reached in patients; e.g. plasma levels of 850 nM [49]. Taken into consideration that the flow resistance increases 16 fold, if the radius divides in half (Hagen-Poiseuille law), the presented vascular effects in human PAs/PVs should be also relevant for human PVR.

These findings suggest a beneficial effect of levosimendan in cardiac surgical patients with PH and also propose its application in non-surgical patients with PH.

Supporting information

S1 Data.
(ZIP)

S2 Data.
(ZIP)

S3 Data.
(ZIP)

Acknowledgments

We gratefully acknowledge Hanna Czajkowska, Nadine Ruske and Xhina Schneider for excellent technical assistance.

Author Contributions

Conceptualization: Annette Dorothea Rieg, Christian Martin.

Data curation: Annette Dorothea Rieg.

Formal analysis: Annette Dorothea Rieg, Said Suleiman, Nina Andrea Bünting, Eva Verjans, Jan Spillner, Heike Schnöring, Sebastian Kalverkamp, Thomas Schröder, Saskia von Stillfried, Till Braunschweig, Gereon Schälte, Stefan Uhlig, Christian Martin.

Investigation: Annette Dorothea Rieg, Said Suleiman, Nina Andrea Bünting, Eva Verjans.

Methodology: Annette Dorothea Rieg, Christian Martin.

Project administration: Annette Dorothea Rieg.

Resources: Annette Dorothea Rieg, Jan Spillner, Heike Schnöring, Sebastian Kalverkamp, Thomas Schröder, Saskia von Stillfried, Till Braunschweig.

Supervision: Annette Dorothea Rieg, Christian Martin.

Validation: Annette Dorothea Rieg, Said Suleiman, Nina Andrea Bünting, Eva Verjans, Jan Spillner, Heike Schnöring, Sebastian Kalverkamp, Thomas Schröder, Saskia von Stillfried, Till Braunschweig, Gereon Schälte, Stefan Uhlig, Christian Martin.
Visualization: Said Suleiman, Nina Andrea Bünting.

Writing – original draft: Annette Dorothea Rieg.

Writing – review & editing: Annette Dorothea Rieg, Eva Verjans, Gereon Schälte, Stefan Uhlig, Christian Martin.

References

1. Farmakis D, Alvarez J, Gal TB, Brito D, Fedele F, Fonseca C, et al (2016) Levosimendan beyond inotropy and acute heart failure: Evidence of pleiotropic effects on the heart and other organs: An expert panel position paper. Int J Cardiol 222: 303–312. S0167-5273(16)31597-2 [pii]; https://doi.org/10.1016/j.ijcard.2016.07.202 PMID: 27498374

2. Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, et al (2012) Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies*. Crit Care Med 40: 634–646. https://doi.org/10.1097/CCM.0b013e318232962a PMID: 22599324

3. Harrison RW, Hasseblad V, Mehta RH, Levin R, Harrington RA, Alexander JH (2013) Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 27: 1224–1232. S1053-0779(13)00171-7 [pii]; https://doi.org/10.1053/j.jvca.2013.03.027 PMID: 24058057

4. Lim JY, Deo SV, Rababah A, Altarabsheh SE, Cho YH, Hang D, et al (2015) Levosimendan Reduces Mortality in Adults with Left Ventricular Dysfunction Undergoing Cardiac Surgery: A Systematic Review and Meta-analysis. J Card Surg 30: 547–554. https://doi.org/10.1111/jocs.12562 PMID: 25989324

5. Comin-Colet J, Manito N, Segovia-Cubero J, Delgado J, Garcia Pinilla JM, Almenar L, et al (2018) Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. https://doi.org/10.1002/ejhf.1145 PMID: 29405611

6. De Witt BJ, Ibrahim IN, Bayer E, Fields AM, Richards TA, Banister RE, et al (2002) An analysis of responses to levosimendan in the pulmonary vascular bed of the cat. Anesth Analg 94: 1427–33. https://doi.org/10.1097/00000539-200206000-00009 PMID: 12032000

7. Kleber FX, Bollmann T, Borst MM, Costard-Jackle A, Ewert R, Kivikko M, et al (2009) Repetitive dosing of intravenous levosimendan improves pulmonary hemodynamics in patients with pulmonary hypertension: results of a pilot study. J Clin Pharmacol 49: 108–115. https://doi.org/10.1177/0091270008325150 PMID: 18981240

8. Rieg AD, Rossaint R, Verjans E, Maihofer NA, Uhlig S, Martin C (2013) Levosimendan Relaxes Pulmonary Arteries and Veins in Precision-Cut Lung Slices—The Role of K-Channels, cAMP and cGMP. PLoS ONE 8: e66195. https://doi.org/10.1371/journal.pone.0066195;PONE-D-12-34289 [pii]. PMID: 23824760

9. Guerrero-Orriach JL, Ariza-Villanueva D, Florez-Vela A, Garrido-Sanchez L, Moreno-Cortes M, Galan-Ortega M, et al (2016) Cardiac, renal, and neurological benefits of preoperative levosimendan administration in patients with right ventricular dysfunction and pulmonary hypertension undergoing cardiac surgery: evaluation with two biomarkers neutrophil gelatinase-associated lipocalin and neuronal enolase. Ther Clin Risk Manag 12: 623–630. https://doi.org/10.2147/TCRM.S102772;tcrm-12-623 [pii]. PMID: 27143905

10. Guerrero Orriach JL, Navarro A, I, Iglesias P, Galan OM, Rubio NM, Cruz MJ (2013) Preoperative levosimendan for right ventricular dysfunction before heart valve replacement surgery. Rev Esp Cardiol (Engl Ed) 66: 999–1000. S1885-5857(13)00183-7 [pii]; https://doi.org/10.1016/j.rec.2013.05.015 PMID: 24774116

11. Hansen MS, Andersen A, Holmboe S, Schultz JG, Ringgaard S, Simonsen U, et al (2017) Levosimendan Prevents and Reverts Right Ventricular Failure in Experimental Pulmonary Arterial Hypertension. J Cardiovasc Pharmacol 70: 232–238. https://doi.org/10.1097/FJC.0000000000000508 PMID: 28640039

12. Hansen MS, Andersen A, Nielsen-Kudsk JE (2018) Levosimendan in pulmonary hypertension and right heart failure. Pulm Circ 8: 2045894018790905. https://doi.org/10.1177/2045894018790905 PMID: 29979110

13. Jiang R, Zhao QH, Wu WH, Zhang R, Yuan P, Gong SG, et al (2017) Efficacy and safety of a calcium sensitizer, levosimendan, in patients with right heart failure due to pulmonary hypertension. Clin Respir J. https://doi.org/10.1111/crj.12695 PMID: 28862394
14. Revermann M, Schloss M, Mieth A, Babelova A, Schroder K, Neofitidou S, et al (2011) Levosimendan attenuates pulmonary vascular remodeling. Intensive Care Med 37: 1368–1377. https://doi.org/10.1007/s00134-011-2254-9 PMID: 21626431

15. Guha A, Amione-Guerra J, Park MH (2016) Epidemiology of Pulmonary Hypertension in Left Heart Disease. Prog Cardiovasc Dis 59: 3–10. S0033-0620(16)30053-6 [pii]; https://doi.org/10.1016/j.pcad.2016.07.001 PMID: 27402130

16. Breitling S, Ravindran K, Goldenberg NM, Kuebler WM (2015) The pathophysiology of pulmonary hypertension in left heart disease. Am J Physiol Lung Cell Mol Physiol 309: L924–L941. https://doi.org/10.1152/ajplung.00146.2015 PMID: 26502478

17. Fayyaz AU, Edwards WD, Maleszewska JJ, Konik EA, Dubrock HM, Borlaug BA, et al (2018) Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Heart Failure and Preserved or Reduced Ejection Fraction. Circulation 137: 1796–1810. CIRCULATIONAHA.117.031608 [pii]; https://doi.org/10.1161/CIRCU LATIONAHA.117.031608 PMID: 29246894

18. Schmeisser A, Schroetter H, Braun-Dulleaus RC (2013) Management of pulmonary hypertension in left heart disease. Ther Adv Cardiovasc Dis 7: 131–151. 1753944713477518 [pii]; https://doi.org/10.1177/1753944713477518 PMID: 23927942

19. Back M, Walch L, Norel X, Gascard JP, Mazmanian G, Brink C (2002) Modification of vascular tone and reactivity by nitric oxide in porcine pulmonary arteries and veins. Acta Physiol Scand 174: 9–15. https://doi.org/10.1046/j.1365-201x.2002.00928.x PMID: 11851592

20. Bonnet S, Archer SL (2007) Potassium channel diversity in the pulmonary arteries and pulmonary veins: implications for regulation of the pulmonary vasculature in health and during pulmonary hypertension. Pharmacol Ther 115: 56–69. S0163-7258(07)00076-9 [pii]; https://doi.org/10.1016/j.pharmthera.2007.03.014 PMID: 17583356

21. Gao Y, Raj JU (2005) Role of veins in regulation of pulmonary circulation. Am J Physiol Lung Cell Mol Physiol 288: L213–L226. 288/2/L213 [pii]; https://doi.org/10.1152/ajplung.00103.2004 PMID: 15640520

22. Raj JU, Ramanathan R, Chen P, Anderson J (1989) Effect of hematocrit on microvascular pressures in 3- to 5-wk-old rabbit lungs. Am J Physiol 256: H766–H771. https://doi.org/10.1152/ajpheart.1989.256.3.H766 PMID: 2923239

23. Mahofer NA, Suleiman S, Dreyrmuller D, Manley PW, Rossaint R, Uhlig S, et al (2017) Imatinib relaxes the pulmonary venous bed of guinea pigs. Respir Res 18: 32. https://doi.org/10.1186/s12931-017-0514-0;10.1186/s12931-017-0514-0 [pii]. PMID: 28179868

24. Rieg AD, Bunting NA, Cranen C, Suleiman S, Spiller JW, Schnoring H, et al (2019) Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices. Respir Res 20: 111. https://doi.org/10.1186/s12931-019-1074-2;10.1186/s12931-019-1074-2 [pii]. PMID: 31170998

25. Schleputz M, Rieg AD, Seehase S, Spiller J, Perez-Bouza A, Braunschweig T, et al (2012) Neurally Mediated Airway Constriction in Human and Other Species: A Comparative Study Using Precision-Cut Lung Slices (PCLS). PLoS ONE 7: e47344. https://doi.org/10.1371/journal.pone.0047344;PONE-D-12-11366 [pii]. PMID: 23056631

26. Rieg AD, Suleiman S, Perez-Bouza A, Braunschweig T, Spiller JW, Schroeder T, et al (2013) Milrinone relaxes pulmonary veins in guinea pigs and humans. PLoS One e87685.

27. Uhlig S, Wollin L (1994) An improved setup for the isolated perfused rat lung. J Pharmacol Toxicol Methods 31: 85–94. https://doi.org/10.1016/1056-8719(94)90047-7 PMID: 8032099

28. Atzori L, Bannenberg G, Corriga AM, Moldeus P, Ryrfeldt A (1992) Sulfur dioxide-induced bronchoconstriction in the isolated perfused and ventilated guinea-pig lung. Respir Physiol 95: 16–21. https://doi.org/10.1016/0034-5687(92)90079-7 PMID: 1579713

29. Martin C, Uhlig S, Ullrich V (1996) Videomicroscopy of methacholine-induced contraction of individual airways in precision-cut lung slices. Eur Respir J 9: 2479–2487. https://doi.org/10.1183/09031936.96.09122479 PMID: 8989057

30. Ressmeyer A, Larsson A, Vollmer E, Dahlen S, Uhlig S, Martin C (2006) Characterisation of guinea pig precision-cut lung slices: comparison with human tissues. Eur Respir J 28: 603–611. https://doi.org/10.1183/09031936.06.0004206 PMID: 16737991

31. Rieg AD, Suleiman S, Perez-Bouza A, Braunschweig T, Spiller JW, Schroeder T, et al (2014) Milrinone relaxes pulmonary veins in guinea pigs and humans. PLoS ONE 9: e87685. https://doi.org/10.1371/journal.pone.0087685;PONE-D-13-18927 [pii]. PMID: 24498166

32. Schneider MP, Boesen EI, Pollock DM (2007) Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol 47: 731–759. https://doi.org/10.1146/annurev.pharmtox.47.120505.105134 PMID: 17002597
Levosimendan reduces segmental pulmonary vascular resistance in rats and relaxes human pulmonary vessels

33. Shao D, Park JE, Wort SJ (2011) The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacol Res 63: 504–511. S1043-6618(11)00067-3 [pii]; https://doi.org/10.1016/j.phrs.2011.03.003 PMID: 21491223

34. Shimoda LA, Shams JS, Liu Q, Sylvester JT (2002) Acute and chronic hypoxic pulmonary vasoconstriction: a central role for endothelin-1? Respir Physiol Neurobiol 132: 93–106. S1569904802000526 [pii]; https://doi.org/10.1016/S1569-9048(02)00052-6 PMID: 12126988

35. Shimoda LA, Laurie SS (2013) Vascular remodeling in pulmonary hypertension. J Mol Med (Berl) 91: 297–309. https://doi.org/10.1007/s00109-013-0998-0 PMID: 23334338

36. Wiklund A, Kythammer D, Radegran G (2012) Levosimendan attenuates hypoxia-induced pulmonary hypertension in a porcine model. J Cardiovasc Pharmacol 59: 441–449. https://doi.org/10.1097/FJC.0b013e31824938f0 PMID: 22420915

37. Ebade AA, Khalil MA, Mohamed AK (2013) Levosimendan is superior to dobutamine as an inodilator in the treatment of pulmonary hypertension for children undergoing cardiac surgery. J Anesth 27: 334–339. https://doi.org/10.1007/s00540-012-1537-9 PMID: 23223915

38. Poidinger B, Kotzinger O, Rutzler K, Kleinsasser A, Zierer A, Knotzer H (2019) Intravenous Levosimendan and Vasopressin in New-Onset Acute Pulmonary Hypertension After Weaning from Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth 33: 328–333. S1053-0770(18)30514-7 [pii]; https://doi.org/10.1053/j.jvca.2018.07.013 PMID: 30122612

39. Chaliki HP, Rurrell DG, Nishimura RA, Reinke RA, Appleton CP (2002) Pulmonary venous pressure: relationship to pulmonary artery, pulmonary wedge, and left atrial pressure in normal, lightly sedated dogs. Catheter Cardiovasc Interv 56: 432–438. https://doi.org/10.1002/cdi.10203 PMID: 12112902

40. Montani D, Price L, Dorfmuller P, Achouh L, Jais X, Yaici A, et al (2009) Pulmonary veno-occlusive disease. Eur Respir J 33: 189–200. https://doi.org/10.1183/09031936.00090608 PMID: 19118230

41. Townsley MI (2012) Structure and composition of pulmonary arteries, capillaries, and veins. Compr Physiol 2: 675–709. https://doi.org/10.1002/cphy.c100081 PMID: 23606929

42. Feeloum M, Girard V, Canet E (1995) Different involvement of nitric oxide in endothelium-dependent relaxation of porcine pulmonary artery and vein: influence of hypoxia. J Cardiovasc Pharmacol 25: 665–673. https://doi.org/10.1097/00005434-199504000-00022 PMID: 7596137

43. Norel X, Walch L, Gascard J, deMontpreville V, Brink C (2004) Prostacyclin release and receptor activation: differential control of human pulmonary venous and arterial tone. Br J Pharmacol 142: 788–796. https://doi.org/10.1038/sj.bjp.0705843 PMID: 15172959

44. Rieg AD, Rossaint R, Uhlig S, Martin C (2011) Cardiovascular agents affect the tone of pulmonary arteries and veins in precision-cut lung slices. PLoS ONE 6: e29698. https://doi.org/10.1371/journal.pone.0029698;PO NE-D-11-15270 [pii]. PMID: 22216346

45. Rieg AD, Suleiman S, Anker C, Verjans E, Rossaint R, Uhlig S, et al (2018) PDGF-BB regulates the pulmonary vascular tone: impact of prostaglandins, calcium. Respir Res 19: 120. https://doi.org/10.1186/s12931-018-0829-5;10 .1186/s12931-018-0829-5 [pii]. PMID: 29921306

46. Usta C, Eksert B, Golbasi I, Bigat Z, Ozdem SS (2006) The role of potassium channels in the vasodilatory effect of levosimendan in human internal thoracic arteries. Eur J Cardiothorac Surg 30: 329–332. https://doi.org/10.1016/j.ejcts.2006.05.019 PMID: 16829109

47. Pataricza J, Hohn J, Petri A, Balogh A, Papp JG (2000) Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 52: 213–217. https://doi.org/10.1016/0022357001773715 PMID: 10714952

48. Pataricza J, Krassoi I, Hohn J, Kun A, Papp JG (2003) Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 17: 115–121. https://doi.org/10.1023/a:1025331617233 PMID: 12975592

49. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Wartliar DC (1999) Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 34: 219–228. https://doi.org/10.1097/00005434-199908000-00007 PMID: 10445673

50. Gruhn N, Nielsen-Kudsk JE, Theiligard S, Bang L, Olesen SP, Aldershville J (1998) Coronary vasorelaxant effect of levosimendan, a new inodilator with calcium-sensitizing properties. J Cardiovasc Pharmacol 31: 741–749. https://doi.org/10.1097/00005434-199805000-00013 PMID: 9593074

51. Endoh M (2007) Could Ca2+ sensitizers rescue patients from chronic congestive heart failure? Br J Pharmacol 150: 826–828. 0707163 [pii]; https://doi.org/10.1038/sj.bjp.0707163 PMID: 17325657

52. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H (1994) Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 266: L536–L543. https://doi.org/10.1152/ajplung.1994.266.5.L536 PMID: 7515580